Developmental Funds

发展基金 项目摘要/摘要 CCSG发展基金利用额外的机构支持，并提供了异常强大的 投资回报。CCSG对新调查员奖励计划的350,000美元支持是 辅以80000美元的机构/慈善基金，分配给8名新聘教员，以及 总共产生了900万美元的赠款支助(总费用)。CCSG为试点项目提供的120万美元支持 项目方案得到了150万美元的机构/慈善基金的补充，产生了1780万美元 100万(总费用)的赠款支持。总计2,680万美元的投资回报(ROI)包括 超过2660万美元的同行评审赠款支持，相当于CCSG资金投资回报率的17.5倍 新调查员奖和试点项目。 CCSG发展基金进一步推动了共享资源的演变。代谢组学共享资源 已成熟为成熟的共享资源，可提供独特的技术专长并易于访问 大多数个人调查员无法使用的最先进的仪器和当前的方案 实验室；这一资源继续推动与普林斯顿大学的合作研究，并在最近 12个月期间，为三个CINJ方案的19名调查员(其中17人是CINJ成员)提供服务。 鉴于CINJ研究企业的持续大幅增长，以及成功地使用 在当前项目期的发展资金中，我们要求每年425,000美元用于 类别：1)招聘CINJ战略优先领域的调查员(新调查员奖 方案)，2)在免疫监测方面开发新的共享资源(响应主任的 免疫肿瘤学)和小分子筛查(对所有基础项目至关重要，特别是 回应2011年对癌症药理学计划的批评)，以及3)试点奖项(试点项目 计划)，以促进与战略优先事项相一致的新颖、协作研究。

DEVELOPMENTAL FUNDS PROJECT SUMMARY/ABSTRACT CCSG developmental funds leveraged additional institutional support and provided an exceptionally strong return on investment. The $350,000 CCSG support of the New Investigator Award Program was supplemented by $80,000 of institutional/philanthropic funds, allocated to eight new faculty recruits, and generated a total of $9 million (total costs) in grant support. The $1.2 million CCSG support of the Pilot Project Program was supplemented by $1.5 million of institutional/philanthropic funds, generating $17.8 million (total costs) in grant support. The grand total of $26.8 million return on investment (ROI) includes over $26.6 million in peer reviewed grant support, and represents a 17.5-fold ROI of CCSG funds invested for New Investigator Awards and Pilot Projects. CCSG developmental funds further enabled shared resource evolution. The Metabolomics shared resource has matured to an established shared resource that offers unique technical expertise and ease-of-access to state-of-the-art instrumentation and current protocols that are not available in most individual investigator laboratories; this resource continues to fuel collaborative research with Princeton University and over a recent twelve-month period, served 19 investigators (17 of whom are CINJ members) across three CINJ programs. Given the continued substantial growth of the CINJ research enterprise, and the successful use of developmental funds in the current project period, we request $425,000 per year to be used in three categories: 1) recruitment of investigators in areas of strategic priority for CINJ (New Investigator Award program), 2) development of new shared resources in Immune Monitoring (responding to the Director’s initiative in Immune Oncology) and Small Molecule Screening (critical to all Basic programs and specifically responsive to a 2011 critique of the Cancer Pharmacology Program), and 3) pilot awards (Pilot Project program) to promote novel, collaborative research aligned with strategic priorities.